-+ 0.00%
-+ 0.00%
-+ 0.00%

Wave Life Sciences Announces Its Data From Ongoing RestorAATion-2 Clinical Study Of WVE-006 Accepted For Presentation At American Thoracic Society International Conference

Benzinga·03/05/2026 13:32:28
Listen to the news

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 mg single dose cohort in addition to data from the 400 mg multidose cohort at the ATS conference in May.